At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anakinra to Prevent Adverse Post-infarction Remodeling (2)
In Brief
A Phase 2 clinical trial evaluating Anakinra and Placebo for Acute Myocardial Infarction and Heart Failure. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality. Many patients die early during the course, and those who survive are at risk for dying late from adverse cardiac remodeling and heart failure. The initial ischemic damage to the myocardium initiates an intense inflammatory response in promoting further cardiac dysfunction and heart failure. The investigators propose that an antiinflammatory strategy based on blockade of Interleukin-1 will quench the inflammatory response and lead to a more favorable cardiac remodeling process.
Study Details
Timeline
Interventions
Anakinra 100 mg s.c. daily for 14 days
0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days